Durlobactam is a novel beta-lactamase inhibitor classified as an antibiotic, developed to treat infections caused by multidrug-resistant Gram-negative bacteria, particularly Acinetobacter species. By inhibiting… Read more
Durlobactam is a novel beta-lactamase inhibitor classified as an antibiotic, developed to treat infections caused by multidrug-resistant Gram-negative bacteria, particularly Acinetobacter species. By inhibiting specific bacterial enzymes, this compound restores the efficacy of traditional penicillin and cephalosporin antibiotics against resistant pathogens. Laboratories working with this pharmaceutical agent rely on high-quality reference standards for accurate impurity profiling and method validation. The Durlobactam products listed here include the active pharmaceutical ingredient alongside related impurities, metabolites, and stable isotope-labelled compounds, which are essential for rigorous quality control and analytical testing procedures. These compounds allow researchers and quality assurance specialists to identify, quantify, and monitor degradation products and metabolic pathways during drug development and routine testing, ensuring compliance with strict safety and efficacy standards throughout the pharmaceutical lifecycle.